Please login to the form below

Not currently logged in

CanSinoBIO considers booster jab for COVID-19 vaccine

Chinese biotech company said the efficacy rate for the one-dose vaccine could decrease over time

The efficacy of Chinese biotech company CanSino Biologics's (CanSinoBio) single-dose COVID-19 vaccine could decrease over time, according to the company’s chief scientific officer Zhu Tao.

During an online presentation on Wednesday, Tao said that the vaccine is likely to retain an efficacy rate of 50% or more five to six months after initial vaccination.

According to the World Health Organization (WHO), a vaccine must have at least a 50% efficacy rate to be considered effective in preventing COVID-19.

Tao added that a booster dose is being considered, with trial participants potentially set to receive a second jab around six months after their first dose.

“A booster shot six months later led to a seven times to ten-times increase in neutralising antibody levels, so we expect in this case efficacy could reach over 90%,” said Tao.

He said, however, that further clinical trial data is required before the exact efficacy can be determined.

Earlier this year, CanSinoBIO revealed that its vaccine was 65.7% effective at preventing symptomatic COVID-19 cases, based on an analysis from late-stage trials, although this dropped to 65.28% after two weeks.

The one-dose COVID-19 vaccine has been approved for use in China, Pakistan, Hungary and Mexico.

Another single-dose vaccine, developed by Johnson & Johnson (J&J), recently received EU authorisation after proving effective in late-stage trials.

J&J’s vaccine was found to be 66% effective overall in preventing moderate-to-severe COVID-19, 28 days after vaccination.

The data also demonstrated that the vaccine was 85% effective in preventing severe disease across all regions and showed protection against COVID-19-related hospitalisation and death, beginning 28 days after vaccination.

Single-dose vaccines have been identified as particularly useful during the pandemic, with advantages including easier storage and ease of use as people are not required to return for a second injection.

mRNA-based vaccines, such as Pfizer/BioNTech and Moderna’s respective jabs, have higher efficacy rates compared to both CanSinoBIO and J&J’s vaccines, but also require ultra-low storage temperatures and are administered as part of a two-dose regimen.

This has raised storage and distribution issues – particularly in developing countries which may not have the infrastructure to support the wide-spread rollout of this type of vaccine.

Article by
Lucy Parsons

1st April 2021

From: Research



Subscribe to our email news alerts

Featured jobs


Add my company
Genetic Digital

Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...

Latest intelligence

5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
ASH 2022: bad blood but big advances
Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....